Please login to the form below

Not currently logged in

BMS appoints new commercial leader, Davies joins Eisai and more

The latest industry movers

Boerner takes on chief commercial role at BMS

Chris Boerner

Bristol-Myers Squibb has announced a new vice president and chief commercial officer in the form of Christopher Boerner (pictured above), who currently serves as its head of International Markets.

Boerner takes over from Murdo Gordon (below), who jumped ship earlier this month to join Amgen as its executive vice president of global commercial operations.

Murdo Gordon

The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck & Co's Keytruda. BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains a powerhouse of growth nonetheless by expanding its uses across more and more tumour types, combinations, and in earlier settings. The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy.

Commenting on the internal promotion, BMS' chief executive Giovanni Caforio said: “Chris brings a deep knowledge of specialty care markets, a clear focus on innovation, and a proven track record of successful execution. Since joining BMS, he has successfully led our commercial organisation across the US and international markets.

““I am confident he will build upon the company’s solid foundation and continue to strengthen our ability to bring medicines to patients faster.”

Boerner initially joined BMS back in early 2015 as head of the US commercial organisation.

Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.

He has also held a number of roles for Dendreon Corporation and Roche’s Genentech, where he worked on its Avastin franchise strategy.

Boerner commented: ““I’m very excited to lead such a talented and diverse commercial team globally.

“Along with my commercial colleagues, I look forward to continuing to help BMS deliver on our mission of bringing transformational medicines to patients.”

Eisai appoints VP, strategic information systems

Stephen Davies

The US subsidiary of Eisai has appointed Stephen Davies (pictured above) as its vice president, Eisai Strategic Information Systems.

Davies will be responsible for leading the pharma group’s IT function for its Americas region, as well as the company’s global clinical and regulatory departments.

Shaji Procida, president & chief operating officer of Eisai, said: “Given his extensive experience as a global enterprise IT leader in the life sciences industry, Stephen will be a tremendous asset for Eisai."

“"We are breaking through in all areas of our business, and innovative technology solutions will play a vital role in helping to propel Eisai into our next phase of expected growth."

Davies joins Eisai from Gartner, where he spend the past four years as a research director, life sciences.

In that role he focused on delivering technology-related insight to help the chief information officer and IT leaders develop strategic decisions related to IT investments, projects and strategies.

Prior to this, Davies served in various roles at Savient Pharmaceuticals and Boehringer Ingelheim.

Apeiron expands board

Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer.

Gaweco will lead Apeiron’s immuno-oncology programmes, overseeing the discovery, clinical and medical functions of the company’s new molecular entities pipeline of cancer immunotherapies.

His new role builds on his career history surrounding drug development through to commercialisation in both pharma and biotech industries.

Peter Llewellyn-Davies, President and CEO of Apeiron, said: "Gaweco’s timely appointment will help chart the continued innovation of our R&D pipeline of cutting-edge cancer immunotherapies, bring forward major near-term milestones of clinical-stage assets and support the expansion and transformative phase of Apeiron.

“His outreach into the worldwide pharmaceutical markets will support the long-term vision and strategy of Apeiron as a leader in cancer immunotherapies."

Gaweco joins the biotech from Innovimmune Biotherapeutics, where he was founder and chief executive/chief scientific officer.

There, he led the discovery of novel immuno-oncology and autoimmune therapeutic programmes.

Prior to this, he was chief medical officer at Lifecycle Pharma, based in Denmark and the USA and has held global clinical leader positions at pharma giants Roche and Pfizer.

Gaweco said: “It will be a privilege to be a part of the team leading Apeiron’s global success in bringing forward its rich pipeline of first-in-class, best-in-class new treatments for cancer patients and to help transform the company into a world-class immuno-oncology leader."

Congenica poaches AZ’s business performance director

Wendy Britten

Currently director of business performance at AstraZeneca, Wendy Britten (pictured) has decided to join Cambridge, UK-based Cogenica, a clinical genomics interpretation software provider.

There, Britten will take responsibility for all financial aspects of the business and will play a key role in business development.

Britten has held senior financial leadership roles prior to this, and aside from her role at AstraZeneca, she has served as director of M&A at PwC.

She said: “I am looking forward to the opportunities that joining the team at Congenica offers. With a strong commitment to positively impacting patient’s lives, Congenica is poised for substantial growth.

“The field of genomic medicine has the potential to revolutionise our approach to rare genetic disease diagnosis and management, as well as in other areas of personalised medicine.”

Led by chief exec David Atkins, Congenica has seen a number of significant developments as of late, including a successful series B financing round that raised $13.5m.

Atkins said: “Britten joins our Senior Management team at a pivotal time in the Company’s development. She brings financial leadership and business development expertise, as we move forward commercially on the back of our successful series B financing last year. Her international experience will support our operational expansion in the UK and across Europe, China and the US.”

Sobi appoints head of technical operations

Rare disease specialist company Sobi has appointed Anne Marie de Jonge Schuermans to front its new technical operations organisation.

Officially joining the biopharma on 1 October, Schuermans will play a part in bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations.

She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.

Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space. I look forward to working with the teams to develop an effective and agile organisation set for growth.”

Bringing more than 15 years of experience in the healthcare industry to her new post as head of technical operations, Schuermans has previously served in various capacities for Styker and Novartis.

Hikma Pharmaceuticals appoints VP, sales and marketing, Generics

Kristy Ronco

Kristy Ronco has been appointed as vice president, sales and marketing, generics for Hikma Pharmaceuticals.

There, she will be responsible for leading its generics business, including retail sales, addiction therapy sales and branded sales teams.

She will also oversee marketing, pricing, forecasting and analytics.

Brian Hoffmann, president of Hikma’s generics division, said:  “I am looking forward to working closely with Kristy and her team to deliver substantial value to our customers, employees and the broader communities we serve.”

Ronco joins Hikma after more than a decade at Zydus Pharmaceuticals, where she was most recently senior vice president, sales and marketing.

Prior to this, she has held roles for TEVA, Sandoz, Aventis and Johnson & Johnson.

Article by
Gemma Jones

28th August 2018

From: Sales



Subscribe to our email news alerts

Featured jobs


Add my company
Say Communications

We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...